We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
PURITAN MEDICAL

Download Mobile App




Rapid AI OCT System Detects Malignant Liver Tissue Intraoperatively

By LabMedica International staff writers
Posted on 23 Jun 2026

Liver cancer commonly requires resection, yet confirming complete tumor removal relies on frozen-section analysis that prolongs anesthesia and ties up operating rooms. More...

Longer cases increase risks for bleeding, infection, and airway or hemodynamic instability, and they add burdens for surgical teams. Faster, dependable intraoperative assessment would improve safety and efficiency. To help address this challenge, researchers have now combined optical coherence tomography with artificial intelligence to accelerate analysis of liver specimens.

The approach pairs optical coherence tomography (OCT) with an anomaly detection algorithm developed by teams at University Hospital RWTH Aachen, the Fraunhofer Institute for Production Technology (IPT), and Fraunhofer Austria Research. OCT provides volumetric, cross‑sectional views of tissue and is already established in ophthalmology. The project adapts this imaging modality for intraoperative use in liver surgery and applies machine learning to distinguish normal parenchyma from malignant tissue.

OCT generates three-dimensional scans using light waves, producing detailed images within seconds. The anomaly detection model is trained only on scans of normal liver parenchyma, enabling it to flag departures from the learned distribution as suspicious. This training paradigm suits settings where nonmalignant samples outnumber malignant ones and allows markedly faster model development than traditional supervised classifiers.

Under laboratory conditions, the collaborators acquired 173 OCT scans from 69 patients at University Hospital RWTH Aachen, including 88 scans of normal liver parenchyma and 85 scans of various tumor types. Applying anomaly detection to human liver OCT images represents a first-of-its-kind combination in this context. The work demonstrates feasibility for rapid, intraoperative decision support.

Classification is produced within seconds, indicating whether a scan reflects normal or tumor tissue, with subsequent confirmation by standard histopathology. Using the available data, the model achieved a mean accuracy of 81%. Depending on tumor type, observed accuracies reached 94.3%, 84.5%, and 65.9%. The findings were published in Scientific Reports.

Next steps include translating the method from laboratory to operating room conditions, miniaturizing the sensor, and integrating the system into surgical workflows as a complement to histopathology. These developments aim to support quicker resections and reduce strain on perioperative teams without sacrificing diagnostic assurance.

“What is special about this method is that the model is trained exclusively on good examples—that is, scans of normal liver parenchyma. The method then reliably detects deviations from this distribution. Using the available data, we achieved a mean accuracy of 81% and have thereby demonstrated that anomaly detection is well-suited as a decision-support tool in this context. Our work has provided the proof of concept,” said Ulrich Krispel, an anomaly detection expert at Fraunhofer Austria.

Related Links
Fraunhofer Austria


Gold Member
Aspiration System
VACUSAFE
Online QC Software
Acusera 24•7
All-in-One Molecular System
AIO M160
Multi-Chamber Washer-Disinfector
WD 390
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to LabMedica.com and get access to news and events that shape the world of Clinical Laboratory Medicine.
  • Free digital version edition of LabMedica International sent by email on regular basis
  • Free print version of LabMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of LabMedica International in digital format
  • Free LabMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Molecular Diagnostics

view channel
Image:Schematic illustration of plasmonic microarray–based KRAS mutation detection from colorectal cancer patients. (Lee, J.Y., Mun, C.W., Kim, E.R. et al. npj Precision Oncology, 2026. https://doi.org/10.1038/s41698-026-01452-8)

Blood and Urine Liquid Biopsy Detects Early Colorectal Cancer Mutations

Early-stage colorectal cancer is difficult to assess noninvasively because tumor-derived mutations occur at extremely low levels in blood and urine, straining the sensitivity, cost, and turnaround time... Read more

Hematology

view channel
Image Credit: Shutterstock

New Biomarkers Predict Resistance to Targeted Therapy in Rare Blood Cancer

Blastic plasmacytoid dendritic cell neoplasm (BPDCN) is a rare and aggressive leukemia with limited treatment options and a poor prognosis. Although tagraxofusp is the first approved targeted therapy for... Read more

Immunology

view channel
Image:Proteomic tear-fluid analysis revealed abnormal patterns in proteins that regulate nerves and T cells in individuals with eye problems (Image Credit: Adobe Stock)

Diagnostic Models Detect Hidden Eye Abnormalities After Mild COVID-19

Persistent ocular symptoms after COVID-19 can severely affect reading, work, and daily tasks, yet standard eye exams often reveal no clear abnormalities. Patients experiencing photophobia, eye pain, and... Read more

Industry

view channel
Photo courtesy of Natera

Natera’s Signatera Earns IVDR Certification for Solid Tumor MRD Testing

Natera’s Signatera has received certification as a Class C device under the European Union’s In Vitro Diagnostic Regulation (IVDR), becoming the first personalized MRD test for solid tumors to achieve... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.